Photonics Healthcare

Photonics Healthcare

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Photonics Healthcare has pioneered the first practical clinical method for measuring oxygen availability inside active human cells using its proprietary protoporphyrin IX triplet state lifetime technique (PpIX-TSLT). Its COMET measurement system is CE-marked for skin measurements and has been validated in multiple clinical trials, demonstrating its potential to provide more relevant physiological information than traditional metrics like lactate or blood pressure. The company is initially targeting perioperative and intensive care settings in Europe, with the long-term vision of expanding to other organs and imaging applications. Its technology addresses a fundamental gap in monitoring cellular metabolism and oxygen utilization.

Critical CarePerioperative MedicineMetabolic Dysfunction

Technology Platform

Protoporphyrin IX Triplet State Lifetime Technique (PpIX-TSLT) for non-invasive, real-time measurement of oxygen partial pressure inside cellular mitochondria.

Funding History

2
Total raised:$5M
Series A$5M
GrantUndisclosed

Opportunities

The technology addresses a fundamental unmet need in critical and perioperative care for direct assessment of cellular health, with potential to reduce complications and lower costs.
The extensible platform allows for expansion into monitoring other organ systems and developing imaging applications, opening multiple new market segments.

Risk Factors

Commercial success depends on changing established clinical practices and securing reimbursement for a novel monitoring parameter.
Technical and regulatory challenges could delay the development of sensors for internal organs beyond the skin.
The company faces competition from larger medtech firms and alternative monitoring solutions.

Competitive Landscape

Photonics Healthcare is a first-mover with a unique photonics-based method for direct mitochondrial oxygen measurement. It faces indirect competition from established companies offering monitoring of surrogate markers (e.g., Edwards Lifesciences for hemodynamics, Masimo for regional oximetry). Its main competition may come from other startups developing novel tissue oxygenation sensors, but the PpIX-TSLT technique appears clinically validated and distinct.